It's been a very busy week for the Contemporary OB/GYN team.
This week's top articles included:
Limited changes occur in endocrine markers with the combined oral contraceptive Nextstellis (Mayne Pharma), according to a prospective study presented at the virtual annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) in March.
The privately held medical device firm Memic Innovative Surgery Ltd. announced in early March that the Food and Drug Administration (FDA) has granted De Novo marketing authorization for its Hominis, a robot-assisted surgical platform for use in single site, natural orifice laparoscopic-assisted transvaginal benign gynecologic procedures, including benign hysterectomy.
Panel will be focused on early detection, screening, and treatment of ovarian cancer.
Gender discrepancy found in ABCA4-associated retinopathy
April 18th 2024A recent meta-analysis suggests sex as a modifying factor in the development of ABCA4-associated retinopathy, revealing a higher proportion of women among individuals with a mild reduced penetrant ABCA4 variant, impacting prognosis predictions and recurrence risks.
Read More